Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - Cardiovascular …, 2020 - Springer
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
[HTML][HTML] Current trends of big data research using the Korean National Health Information Database
MK Kim, K Han, SH Lee - Diabetes & Metabolism Journal, 2022 - synapse.koreamed.org
Recently, medical research using big data has become very popular, and its value has
become increasingly recognized. The Korean National Health Information Database (NHID) …
become increasingly recognized. The Korean National Health Information Database (NHID) …
Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
YS Lyu, S Oh, JH Kim, SY Kim, MH Jeong - Cardiovascular Diabetology, 2023 - Springer
Background Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have
demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus, real-world …
demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus, real-world …
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: a …
SJ Han, KH Ha, N Lee, DJ Kim - Diabetes, Obesity and …, 2021 - Wiley Online Library
Aim To examine the real‐world cardiovascular effectiveness and safety associated with
sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with dipeptidyl peptidase‐4 …
sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor compared with dipeptidyl peptidase‐4 …
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
During the last decade we experienced a surge in the number of glucose lowering agents
that can be used to treat patients with type 2 diabetes. Especially important are the …
that can be used to treat patients with type 2 diabetes. Especially important are the …
Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017–2020: a multicenter …
Background COVID-19 has worse mortality than influenza in American and European
studies, but evidence from the Western Pacific region is scarce. Methods Using a large-scale …
studies, but evidence from the Western Pacific region is scarce. Methods Using a large-scale …
[HTML][HTML] SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort …
A Mascolo, C Scavone, L Scisciola, P Chiodini… - Pharmacological …, 2021 - Elsevier
Despite Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been associated with a
reduced risk of heart failure in patients with type 2 diabetes mellitus (T2DM), the effect …
reduced risk of heart failure in patients with type 2 diabetes mellitus (T2DM), the effect …
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular …
Aims We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i)
versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart …
versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart …
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Aims The aim of this article is to explore the influence of region and race/ethnicity on the
effects of empagliflozin in the Empagliflozin Outcome Trial in Patients with Chronic Heart …
effects of empagliflozin in the Empagliflozin Outcome Trial in Patients with Chronic Heart …